AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 JAN 1 - (NewsRx.com & NewsRx.net) -- Insmed, Inc., (INSM) reported on data from recent studies of the company's proprietary anticancer compound, recombinant human insulin-like growth factor binding protein-3 (rhIGFBP-3).
These studies conducted in the laboratory of Dr. Brian Leyland-Jones of McGill University were designed to explore the ability of rhIGFBP-3 to sensitize breast cancer cells to Herceptin (Trastuzumab).
The results of this study, published in the abstract titled, "Recombinant human insulin-like growth factor binding protein-3 (rhIGFBP-3) as a potential therapeutic agent for the treatment of Herceptin-resistant breast cancer," demonstrated the following:
1) In Herceptin-resistant breast carcinoma cells there was an increased level of insulin-like growth factor receptor.
2) rhIGFBP-3 caused dose-dependent inhibition of Herceptin-resistant breast carcinoma growth.
3) rhIGFBP-3 in ...